Prognostic value of urokinase plasminogen activator system in non‑small cell lung cancer: A systematic review and meta‑analysis
Authors:
- 3 November 2017
- journal article
- review article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 8 (1) , 127-132
Abstract
Current relevant research suggests there are significant differences between the expression of the urokinase plasminogen activator (uPA) system in cancer tissues and in normal tissues. However, the potential effectiveness of the uPA system as a prognostic biomarker of non‑small cell lung cancer (NSCLC) remains unclear. In the present study, a systematic review and meta‑analysis were performed to evaluate the relevance of the uPA system in the prognosis of patients with NSCLC. Using the PubMed, EMBASE, Web of Science and Cochrane Library databases, data from relevant academic journal articles were extracted and subjected to analysis. Associations between expression profiles pertaining to the uPA system and the overall survival (OS) of patients with NSCLC were analyzed. The study incorporated data from 11 independent journal articles and these reports included a total of 937 patients with NSCLC. The meta‑analysis results revealed that increased expression of urokinase plasminogen activator (uPA) and PA inhibitor type 1 (PAI‑1) exhibited no significant association with poor OS [hazard ratio (HR)‑uPA=1.07 (0.87‑1.31), P=0.53; HR‑PAI‑1=1.02 (0.63‑1.65), P=0.94]. Similarly, reduced expression of PAI type 2 (PAI‑2) did not significantly correlate with poor OS [HR‑PAI‑2=1.58 (0.64‑3.90); P=0.32]. Notably, however, a significant association was observed between increased expression levels of uPA receptor (uPAR) and poor OS for NSCLC [HR‑uPAR=1.50 (1.04‑2.15); P=0.03]. Therefore, the expression of uPAR in the uPA system of patients with NSCLC could be used as a novel clinical biomarker to evaluate the prognosis of NSCLC. The utilization of this biomarker may provide a platform for the further development of targeted drugs for the treatment of NSCLC.Keywords
This publication has 27 references indexed in Scilit:
- Role of Urokinase Receptor in Tumor Progression and DevelopmentTheranostics, 2013
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator ReceptorJournal of Oncology, 2012
- High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasisWorld Journal of Gastroenterology, 2012
- Incidence and risk factors of recurrent acute lung injury*Critical Care Medicine, 2011
- Epigenetic Upregulation of Urokinase Plasminogen Activator Promotes the Tropism of Mesenchymal Stem Cells for Tumor CellsMolecular Cancer Research, 2010
- Regulation of cell signalling by uPARNature Reviews Molecular Cell Biology, 2010
- Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non‐small cell lung cancerAPMIS, 2009
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissueLung Cancer, 2005